NEW YORK – While many in the US and Europe have only recently come to understand the scope and severity of the SARS-CoV-2 pandemic, a handful of proteomics labs have been studying the virus since the beginning of the year.
These studies have yielded potential drug targets, some of which are now being tested, as well as information that could potentially aid the development of more rapid diagnostics for the virus.